Plain-English translation of NCT07380113 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether a medication called works as well as —another medication already used to treat severe itching—to help people on dialysis sleep better. Severe itching is a common and distressing problem for people with chronic kidney disease who receive regular hemodialysis, and it often disrupts their sleep. The study will compare how well each medication reduces itching and improves sleep quality over 4 weeks.
People on dialysis often experience intense, unrelenting itching that can severely affect their quality of life and sleep. While is already available for this problem, researchers want to see if —a newer medication—might be just as effective or better, and to understand how these treatments work at the biological level.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive one of two treatments for 4 consecutive weeks. If assigned to , you will receive an injection (0.3 μg/kg) three times per week, given after your regular dialysis sessions. If assigned to , you will take an orally disintegrating tablet (2.5 μg) by mouth once daily after dinner. Throughout the study, you will complete questionnaires about your itching severity, sleep quality, and quality of life. The research team will monitor your vital signs, check your blood work, and ask about any side effects to make sure the treatment is safe and working.
AI-generated summary from trial data · Aug 28, 2026 · Not medical advice
China